 |
53 Diseases |  |
490 Trials |
|
490 Trials |  |
8927 News |  |
| «12...5758596061626364656667...123124» |
- |||| Clinical, HEOR: Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study https://t.co/CBDvyOOCNz (Twitter) - May 12, 2022
- | lenvatinib / Generic mfg.
Journal: The AGH score is a predictor of disease-free survival and targeted therapy efficacy after liver transplantation in patients with hepatocellular carcinoma. (Pubmed Central) - May 12, 2022
The AGH scoring system provides a convenient and effective way to predict HCC recurrence after LT in HCC patients in China. Patients with a high-risk AGH score may benefit from lenvatinib adjuvant therapy after LT.
- lenvatinib / Generic mfg., sorafenib / Generic mfg.
Risk factors for hepatic encephalopathy in hepatocellular carcinoma after sorafenib or lenvatinib treatment: a real-world study (Poster Area) - May 12, 2022 - Abstract #EASLILC2022EASL_ILC_2240;
uHCC patients with cirrhosis who receive LEN are more likely to develop HE than SOR, with alcohol-related cirrhosis, Child- Pugh Score, serum ammonia, total bile acid, and duration of treatment to be risk factors for HE. Friday 24 June Acute liver failure and drug induced liver injury
- | lenvatinib / Generic mfg.
Journal: Transarterial chemoembolization plus a PD-1 inhibitor with or without lenvatinib for intermediate-stage hepatocellular carcinoma. (Pubmed Central) - May 12, 2022
Friday 24 June Acute liver failure and drug induced liver injury The combination of TACE with a PD-1 inhibitor and lenvatinib in patients with BCLC stage B HCC might result in significantly improved clinical outcomes with a manageable safety profile compared with TACE with a PD-1 inhibitor.
- Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
Atezolizumab Plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: An international study (Auditorium A; Level 0) - May 12, 2022 - Abstract #ESMOGI2022ESMO_GI_501;
For the primary and secondary endpoints, we performed the analysis firstly on the whole population, then we divided the cohort into two groups NASH/NAFLD and non-NASH/NAFLD population. Conclusions The present analysis conducted on a large number of advanced non-viral HCC patients showed for the first time a significant survival benefit with lenvatinib compared to atezolizumab plus bevacizumab, in particular in patients with NASH/NAFLD-related HCC.
- OTX-2002 / Omega Therap
Modulation of the MYC oncogene using programmable epigenetic mRNA therapeutics as a novel therapy for hepatocellular carcinoma () - May 12, 2022 - Abstract #ESMOGI2022ESMO_GI_471;
Targeting MYC in this manner may represent a new and potentially effective approach to the treatment of HCC, either as a single agent or in combination with various approved or investigational therapeutics. Omega plans to submit an IND for OTX-2002 in HCC in 1H2022.
- Keytruda (pembrolizumab) / Merck (MSD)
Open-label, randomized, phase 3 study of first-line lenvatinib plus pembrolizumab plus chemotherapy in esophageal squamous cell carcinoma: LEAP-014 trial in progress () - May 12, 2022 - Abstract #ESMOGI2022ESMO_GI_463;
P3
Prior data also suggest promising antitumor activity of lenvatinib plus pembrolizumab in advanced solid tumors. LEAP-014 (NCT04949256) is a randomized, 2-part, open-label, phase 3 study that will evaluate the efficacy and safety of first-line lenvatinib plus pembrolizumab plus chemotherapy versus pembrolizumab plus chemotherapy in patients with metastatic esophageal squamous cell carcinoma (ESCC).
- Avastin (bevacizumab) / Roche
Impact of relative dose intensity of bevacizumab in first-line treatment of hepatocellular cancer () - May 12, 2022 - Abstract #ESMOGI2022ESMO_GI_410;
Background Atezolizumab-Bevacizumab (AB) is the current standard of care for treatment of unresectable hepatocellular cancer (HCC), with the recommended dosage of bevacizumab at 15mg/kg...A relative dose intensity (RDI) of ā„70% is correlated with better overall survival (OS) and radiological responses for other first-line therapies for HCC like Lenvatinib...Use of reduced dose bevacizumab can be considered to reduce cost and toxicity without significantly affecting treatment outcomes. This should be explored further in a prospective setting.
- lenvatinib / Generic mfg.
Lenvatinib activates potential anti-tumor immunity by increasing infiltration of immune cells and interferon response in tumor microenvironment of advanced hepatocellular carcinoma () - May 12, 2022 - Abstract #ESMOGI2022ESMO_GI_308;
Our findings could expand the possibility of lenvatinib as a potentiator of immune blockade therapies. With limited number of samples as exploratory analysis, further analysis is required to clarify the details of tumor microenvironment and biomarker research for optimized treatment selection and less invasively diagnosis.
- Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
Patient preferences for unresectable hepatocellular carcinoma (HCC) treatments: Balancing overall survival and quality of life () - May 12, 2022 - Abstract #ESMOGI2022ESMO_GI_291;
Conclusions Patients with unresectable HCC prioritized avoiding side effects that would severely impact their quality of life during treatment much more compared with mode and frequency of treatment administration and digestive tract bleeding risk. For patients with unresectable HCC, the ability to maintain quality of life and conduct daily activities is as important or more important than a treatment's survival benefit.
- Discussant: O-5, SO-12, SO-13, SO-14, SO-15 (Auditorium A; Level 0) - May 12, 2022 - Abstract #ESMOGI2022ESMO_GI_121;
For patients with unresectable HCC, the ability to maintain quality of life and conduct daily activities is as important or more important than a treatment's survival benefit. Learning Objectives: O-5: Outcomes by baseline liver function in patients with unresectable hepatocellular carcinoma treated with tremelimumab and durvalumab in the Phase 3 HIMALAYA study - Arndt Vogel, et al SO-12: Nivolumab (NIVO) plus ipilimumab (IPI) combination therapy in patients with advanced hepatocellular carcinoma (aHCC): 5-year results from CheckMate 040 - Ignacio Melero, et al SO-13: Pembrolizumab in patients with advanced hepatocellular carcinoma (aHCC) previously treated with sorafenib: updated data from the open-label, phase 2 KEYNOTE-224 study - Arndt Vogel, et al SO-14: Atezolizumab Plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: An international study - Andrea Casadei-Gardini, et al SO-15: Impact of sequencing of different treatment modalities on survival outcomes among patients with non-metastatic hepatocellular carcinoma - Firas Baidoun, et al
- sorafenib / Generic mfg.
Tyrosine kinase inhibitors (TKIs) plus transarterial chemoembolization (TACE) compared to TACE alone as downstaging therapy in transplant recipients with hepatocellular carcinoma () - May 11, 2022 - Abstract #ESMOGI2022ESMO_GI_330;
P2
(TACE) plus lenvatinib led showed significant improvement in OS compared to lenvatinib alone in the first-line setting in patients with advanced HCC according to phase 3 LAUNCH trial which was presented at the 2022 ASCO Gastrointestinal Cancers Symposium...Conclusions We have found that using TandS is generally well tolerated and demonstrated improved OS compared to TA in patients with unresectable HCC. A prospective clinical study (NCT05171335) is ongoing at our institution to further investigate this concept.
- lenvatinib / Generic mfg.
Trial in progress: Neoadjuvant combination therapy of lenvatinib plus transcatheter arterial chemoembolization (TACE) for transplant-eligible patients with large hepatocellular carcinoma () - May 11, 2022 - Abstract #ESMOGI2022ESMO_GI_328;
P2
To test this hypothesis, we propose a regimen of six months of neoadjuvant Lenvatinib in combination with TACE prior to transplantation. We aim to improve the response (defined as the percent tumor necrosis present on the explanted liver at the time of transplantation) by adding lenvatinib in combination with TACE.
- ||| lenvatinib / Generic mfg.
Amber Specialty Pharmacy Added to Eisai’s LENVIMA® Network https://t.co/yFXn2GYCkR (Twitter) - May 11, 2022
- | lenvatinib / Generic mfg.
Journal: MRI-based Nomogram Predicts the Risk of Progression of Unresectable Hepatocellular Carcinoma After Combined Lenvatinib and anti-PD-1 Antibody Therapy. (Pubmed Central) - May 11, 2022
We aim to improve the response (defined as the percent tumor necrosis present on the explanted liver at the time of transplantation) by adding lenvatinib in combination with TACE. MRI features can be considered effective predictors of disease progression for unresectable HCC with first-line lenvatinib plus anti-PD-1 antibody therapy, and the combined MRI-based nomogram achieved a superior prognostic model, which may help to identify appropriate candidates for the therapy.
- | lenvatinib / Generic mfg.
Journal: Efficacy and Safety of TACE Combined With Lenvatinib Plus PD-1 Inhibitors Compared With TACE Alone for Unresectable Hepatocellular Carcinoma Patients: A Prospective Cohort Study. (Pubmed Central) - May 10, 2022
Compared with TACE, the combination treatment demonstrated an improved clinical efficacy and manageable safety profile in patients with uHCC. Combination treatment showed better therapeutic efficacy in patients with low NLR; therefore, this ratio could be used to identify patients who will benefit from this treatment.
- | lenvatinib / Generic mfg.
Journal: Associations Between Plasma Concentrations of Lenvatinib and Angiopoietin and Clinical Responses to Lenvatinib Therapy in Japanese Patients With Thyroid Cancer. (Pubmed Central) - May 10, 2022
Combination treatment showed better therapeutic efficacy in patients with low NLR; therefore, this ratio could be used to identify patients who will benefit from this treatment. The decrease in Ang-2 at 1 month of treatment from baseline may be important as a biomarker of the inhibitory effect of lenvatinib on angiogenesis.
- | Journal: Recent Progress in Systemic Therapy for Hepatocellular Cancer (HCC). (Pubmed Central) - May 10, 2022
Moreover, patients now have multiple options available in second-line therapy including targeted therapies like sorafenib, lenvatinib, regorafenib, cabozantinib, ramucirumab and immunotherapies like atezolizumab, and nivolumab either alone or combined with ipilimumab...Combination therapy with atezolizumab-bevacizumab has recently become the standard first line of therapy for patients with advanced HCC. Additionally, immunotherapy agents are poised to play a significant role in the management of HCC either alone or in combination with molecular targeted therapies.
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion date, Combination therapy: Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including Central Nervous System Tumors (clinicaltrials.gov) - May 10, 2022
P1/2, N=120, Active, not recruiting, Sponsor: Eisai Inc.
Additionally, immunotherapy agents are poised to play a significant role in the management of HCC either alone or in combination with molecular targeted therapies. Trial completion date: May 2022 --> Dec 2022
- | Retrospective data, Journal, HEOR: Cost-Effectiveness Analysis of Five Systemic Treatments for Unresectable Hepatocellular Carcinoma in China: An Economic Evaluation Based on Network Meta-Analysis. (Pubmed Central) - May 9, 2022
Sensitivity and scenario analysis results showed that the base-case analysis was highly reliable. Although combination therapy could greatly improve patients with uHCC survival benefits, under the current WTP, donafenib is still the most economical option.
- lenvatinib / Generic mfg.
Clinical observation of D-TACE combined with lenvatinib for advanced hepatocellular carcinoma () - May 9, 2022 - Abstract #ECIO2022ECIO_54;
Although combination therapy could greatly improve patients with uHCC survival benefits, under the current WTP, donafenib is still the most economical option. D-TACE combined with lenvatinib in the treatment of advanced HCC can significantly improve the short-term efficacy, and does not increase the toxic and side effects.
- The first-line systemic therapy in advanced hepatocellular carcinoma: an updated network meta-analysis () - May 9, 2022 - Abstract #ECIO2022ECIO_42;
This network meta-analysis of 9 trials found that both sintilimab plus IBI305 and atezolizumab plus bevacizumab can be considered the standard of care in the first-line setting in patients with advanced HCC. Other potential combinations and the efficacy in patients with suboptimal liver function should be explored in the future
- ||||| Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment closed, Metastases: LEAP-001 China Extension: Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001) - China Extension Study (clinicaltrials.gov) - May 8, 2022
P3, N=875, Active, not recruiting, Sponsor: Merck Sharp & Dohme LLC
Other potential combinations and the efficacy in patients with suboptimal liver function should be explored in the future Recruiting --> Active, not recruiting
- | MK-2206 / Merck (MSD), Koselugo (selumetinib) / Merck (MSD), AstraZeneca
Journal: Regulation of Expression of Sterol Regulatory Element-binding Protein 1 in Thyroid Cancer Cells. (Pubmed Central) - May 7, 2022
The galectin-3 inhibitor attenuates SREBP1 expression in thyroid cancer cells, likely independent of AKT phosphorylation. Lenvatinib and selumetinib decreases SREBP1 expression in the BRAF-mutant cell line BHT-101.
- | lenvatinib / Generic mfg.
Journal: Inactivation of AKT/ERK Signaling and Induction of Apoptosis Are Associated With Amentoflavone Sensitization of Hepatocellular Carcinoma to Lenvatinib. (Pubmed Central) - May 7, 2022
Lenvatinib and selumetinib decreases SREBP1 expression in the BRAF-mutant cell line BHT-101. Amentoflavone sensitization of HCC to lenvatinib is associated with AKT/ERK inactivation and apoptosis induction.
- || Farydak (panobinostat) / Secura Bio, Torisel (temsirolimus) / Pfizer
Biomarker, Clinical data, Journal, Tumor Mutational Burden, Tumor microenvironment, IO biomarker, Epigenetic controller: Identification of Tumor Microenvironment and DNA Methylation-Related Prognostic Signature for Predicting Clinical Outcomes and Therapeutic Responses in Cervical Cancer. (Pubmed Central) - May 7, 2022
Finally, four drugs (panobinostat, lenvatinib, everolimus, and temsirolimus) were found to have potential therapeutic implications for patients with a high-risk score. Our findings highlight that the TME and DNA methylation-related prognostic signature can accurately predict the prognosis of CC and may be important for stratified management of patients and precision targeted therapy.
- | Nexavar (sorafenib) / Bayer, Amgen
Journal, HEOR: Indirect Comparisons via Sorafenib for the Comparative Effectiveness of Two PD-1/PD-L1 Inhibitors to Treat Advanced Hepatocellular Carcinoma Patients without Prior Systemic Therapies. (Pubmed Central) - May 7, 2022
In the second-order comparison, AB was insignificantly more efficacious on OS (HR: 0.71, 95% CI: 0.42-1.23) than and similarly efficacious on PFS (HR: 0.95, 95% CI: 0.60-1.51) as the LP regimen. LP regimen may be a potential first-line immunotherapy option for advanced HCC given its comparative effectiveness in relation to AB.
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion date, Trial primary completion date, Metastases: Lenvatinib and Everolimus in Renal Cell Carcinoma (RCC) (clinicaltrials.gov) - May 6, 2022
P1, N=15, Recruiting, Sponsor: Yousef Zakharia
LP regimen may be a potential first-line immunotherapy option for advanced HCC given its comparative effectiveness in relation to AB. Trial completion date: Apr 2022 --> Apr 2024 | Trial primary completion date: Apr 2022 --> Apr 2023
- | Keytruda (pembrolizumab) / Merck (MSD)
Journal, Tumor Mutational Burden, MSi-H Biomarker, PD(L)-1 Biomarker, IO biomarker: Changing treatments paradigms and role of immunotherapy in recurrent endometrial cancer. (Pubmed Central) - May 6, 2022
We outline the role of testing for uterine cancer and its implication in therapy management. Finally, we address new concepts for immunotherapy combinations with other therapies.
- | lenvatinib / Generic mfg.
Journal: Lenvatinib induces cardiac developmental toxicity in zebrafish embryos through regulation of Notch mediated-oxidative stress generation. (Pubmed Central) - May 6, 2022
Additionally, we found that lenvatinib downregulated Notch signaling, and the activation of Notch signaling could rescue cardiac developmental defects and downregulate oxidative stress level induced by lenvatinib. Our results suggested that lenvatinib might induce cardiac developmental toxicity through inducing Notch mediated-oxidative stress generation, raising concerns about the harm of exposure to lenvatinib in aquatic organisms.
- ||| Review, Journal, Adverse events, Checkpoint inhibition: Dermatological adverse events associated with immune checkpoint inhibitor-based combinations of anticancer therapies: a systematic review. (Pubmed Central) - May 6, 2022
The dermatological AEs reported were mutually inclusive and the highest incidence of specific AEs was seen in the following combinations: rash in the nivolumab/ipilimumab and lenvatinib/pembrolizumab combinations, pruritus in the atezolizumab/nab-paclitaxel combination, dry skin and palmar-plantar erythrodysesthesia in the axitinib/pembrolizumab combination, and alopecia and severe skin reactions in the pembrolizumab/carboplatin/paclitaxel combination. Knowledge of such side effects is of benefit when choosing an optimal treatment regimen and should be integrated into the monitoring and follow-up phases of treatment.
- || Review, Journal, PD(L)-1 Biomarker, IO biomarker: Approaches to First-Line Therapy for Metastatic Clear Cell Renal Cell Carcinoma. (Pubmed Central) - May 6, 2022
The four IO-based combinations reviewed are ipilimumab/nivolumab (IO/IO), pembrolizumab/axitinib (IO/TKI), nivolumab/cabozantinib (IO/TKI), and pembrolizumab/lenvatinib (IO/TKI)...IO/IO and IO/TKI combinations for mccRCC have distinct efficacy and toxicity profiles. Future studies are needed to identify biomarkers to optimize patient outcomes.
- || Keytruda (pembrolizumab) / Merck (MSD)
Clinical, Journal, Real-world evidence: Real-world experience of pembrolizumab and lenvatinib in recurrent endometrial cancer: A multicenter study in Korea. (Pubmed Central) - May 6, 2022
Future studies are needed to identify biomarkers to optimize patient outcomes. In our real-world study, Korean patients with recurrent EC who received PEMBRO+LEN showed lower treatment response rate and similar treatment discontinuation rate, compared to clinical trials.
- | lenvatinib / Generic mfg.
Retrospective data, Journal: Transarterial Chemoembolization Combined With Lenvatinib Plus PD-1 Inhibitor for Advanced Hepatocellular Carcinoma: A Retrospective Cohort Study. (Pubmed Central) - May 6, 2022
The incidence and severity of AEs in TACE-L-P group were comparable to those in TACE-L group (any grade, 92.7% vs. 95.0%, P=1.000; grade 3, 36.6% vs. 32.5%, P=0.699). TACE-L-P significantly improved survival over TACE-L with an acceptable safety profile in advanced HCC patients, especially those with extrahepatic metastasis or tumor number >3 but without main portal vein invasion.
- || Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / Ono Pharma, BMS, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
Retrospective data, Review, Journal: New first-line immunotherapy-based combinations for metastatic renal cell carcinoma: A systematic review and network meta-analysis. (Pubmed Central) - May 6, 2022
Although we established a ranking among new first-line mRCC treatment combinations, the absence of direct comparisons between the multiple treatment options represents a major hurdle in establishing optimal therapeutic sequences. Our results could represent a starting point for head-to-head trials between the most promising combinations.
- | lenvatinib / Generic mfg.
Retrospective data, Journal, Checkpoint inhibition: A Retrospective Study on Therapeutic Efficacy of Transarterial Chemoembolization Combined With Immune Checkpoint Inhibitors Plus Lenvatinib in Patients With Unresectable Hepatocellular Carcinoma. (Pubmed Central) - May 6, 2022
TACE in combination with lenvatinib plus anti-PD-1 inhibitors may have promising antitumor activity in uHCC. Toxicities were manageable, with no unexpected safety signals.
- | Keytruda (pembrolizumab) / Merck (MSD)
Biomarker, Trial completion date, Trial primary completion date, Tumor mutational burden: KeyImPaCT: A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495) (clinicaltrials.gov) - May 5, 2022
P2, N=318, Active, not recruiting, Sponsor: Merck Sharp & Dohme LLC
Toxicities were manageable, with no unexpected safety signals. Trial completion date: Oct 2025 --> Jun 2025 | Trial primary completion date: Oct 2025 --> Jun 2025
- ||||| Keytruda (pembrolizumab) / Merck (MSD), lenvatinib / Generic mfg.
Clinical: ICYMI: @DrRoyHerbstYale, of @YaleCancer, discusses exploring immunotherapy/TKI combinations like pembro plus lenvatinib in patients with non–small cell lung cancer, and outlined the different efforts that comprise the LEAP clinical trial program. #lcsm https://t.co/fyneiCpQhR (Twitter) - May 3, 2022
- || Review, Tumor Mutational Burden, PD(L)-1 Biomarker, IO biomarker: How Immunotherapy Modified the Therapeutic Scenario of Endometrial Cancer: A Systematic Review. (Pubmed Central) - May 3, 2022
Anti-PD1 (pembrolizumab, nivolumab, dostarlimab) and anti-PD-L1 agents (avelumab, atezolizumab, durvalumab) were administered as single agents; pembrolizumab and nivolumab were combined with the tyrosine-kinase inhibitors (TKI) lenvatinib and cabozantinib, respectively; and durvalumab was associated with anti-CTLA4 tremelimumab...Ongoing randomized trials will further clarify the role of these therapeutic options. PROSPERO, CRD42021293538.
- | lenvatinib / Generic mfg.
Journal: Apparent Diffusion Coefficient MRI Shows Association With Early Progression of Unresectable Intrahepatic Cholangiocarcinoma With Combined Targeted-Immunotherapy. (Pubmed Central) - May 1, 2022
PROSPERO, CRD42021293538. Pretreatment MRI features were associated with EP for unresectable ICC treated with combined targeted-immunotherapy, and decreased ADC value was an independent variable.
- | Stivarga (regorafenib) / Bayer
Journal: Synergistic Anti-Angiogenic Effect of Combined VEGFR Kinase Inhibitors, Lenvatinib, and Regorafenib: A Therapeutic Potential for Breast Cancer. (Pubmed Central) - Apr 30, 2022
Therefore, it shows their therapeutic potential in breast cancer, including the aggressive types. Further studies are warranted to confirm and explore this therapeutic approach.
- | lenvatinib / Generic mfg.
Journal: Proangiogenesis effects of compound danshen dripping pills in zebrafish. (Pubmed Central) - Apr 30, 2022
CDDP has a proangiogenic effect, the mechanism of which involves the VEGF/VEGFR and PI3K/AKT signaling pathways. These results suggest a new insight into the cardiovascular protective effect of CDDP.
- | Nexavar (sorafenib) / Bayer, Amgen
Journal: Treatment of hepatocellular carcinoma with autologous platelets encapsulating sorafenib or lenvatinib: a novel therapy exploiting tumor-platelet interactions. (Pubmed Central) - Apr 29, 2022
By liquid chromatography-mass spectrometry, more abundant sorafenib was detected in tumor tissues after SOR-PLT administration than in surrounding normal tissues, but no such difference in sorafenib level was observed with SOR administration. Therefore, the use of autologous platelets encapsulating drugs might be a novel therapeutic strategy for HCC.
- || Avastin (bevacizumab) / Roche, Nexavar (sorafenib) / Bayer, Amgen, Tecentriq (atezolizumab) / Roche
Review, Journal: Systemic Therapy in Metastatic Hepatocellular Carcinoma. (Pubmed Central) - Apr 29, 2022
Lenvatinib, a multikinase inhibitor, is also a new first line treatment option for patients who are not eligible for immunotherapy...However, these new therapies are primarily approved for patients with Child-Pugh A classification with few options for patients with Child-Pugh B disease. Further work is needed to expand options for patients with more advanced liver disease and to optimize the sequencing of these new therapies.
- ||| Keytruda (pembrolizumab) / Merck (MSD), lenvatinib / Generic mfg.
HRQoL data from #CLEAR trial of lenvatinib plus pembrolizumab in advanced RCC published yesterday in @TheLancetOncol 👉https://t.co/Pm7vmTwGLM👈 Click below for our ASCO21 report of the findings by @motzermd @CPRT65 @DrChoueiri & colleagues @uroupdate https://t.co/hYgYBcpYOP (Twitter) - Apr 28, 2022
- || Review, Journal, PD(L)-1 Biomarker, IO biomarker: Immunotherapies for hepatocellular carcinoma. (Pubmed Central) - Apr 28, 2022
In addition, pembrolizumab monotherapy and the combination of nivolumab plus ipilimumab have received FDA Accelerated Approval in the second-line setting based on early efficacy data...In addition, current evidence from phase III trials on the efficacy, immune-related adverse events and aetiology-dependent mechanisms of response are described. Finally, we discuss emerging trials assessing immunotherapies across all stages of HCC that might change the management of this disease in the near future.
- || lenvatinib / Generic mfg.
Clinical, Journal: Influence of skeletal muscle volume loss during lenvatinib treatment on prognosis in unresectable hepatocellular carcinoma: a multicenter study in Tohoku, Japan. (Pubmed Central) - Apr 28, 2022
Multivariate analysis revealed a significant association of severe atrophy with OS (hazard ratio 1.927, Pā=ā0.031). Progressive loss of SMV is a strong predictor of poor prognosis in HCC patients taking lenvatinib.
- |||| Clinical, HEOR: Health-related quality-of-life outcomes in patients w/advanced renal cell carcinoma treated with lenvatinib + pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study - @TheLancetOncol @motzermd @CellaDavid https://t.co/2a0Bx7pMwB (Twitter) - Apr 28, 2022
- | Nexavar (sorafenib) / Bayer, Amgen
Journal: Differences Between Sorafenib and Lenvatinib Treatment from Genetic and Clinical Perspectives for Patients with Hepatocellular Carcinoma. (Pubmed Central) - Apr 28, 2022
There were no significant differences in nausea, fatigue, frequent urination, and dizziness (P>0.05). CONCLUSIONS In a time of increasing interest in chemotherapy drug treatments for patients with HCC, this study provided a better understanding of the clinical evaluations of sorafenib and lenvatinib.
- ||| lenvatinib / Generic mfg.
Journal, Adverse events: Lenvatinib Therapy for Advanced Thyroid Cancer: Real-Life Data on Safety, Efficacy, and Some Rare Side Effects. (Pubmed Central) - Apr 28, 2022
We also report 2 severe and rarely described AEs that physicians should watch for. As for efficacy, although less than in the SELECT trial, ORR and PFS were similar to other real-life studies.